FDA Asks Bristol For Corrective Avapro, Glucophage and Taxol Advertising
Executive Summary
Bristol-Myers Squibb must develop a "multifaceted" corrective advertising campaign for Avapro, Glucophage and Taxol promotions cited by FDA for repeated violations in a March 16 warning letter.